Philip Sager

Dr. Sager is a cardiologist and electrophysiologist who has held senior leadership positions within the pharmaceutical industry and academia and has played a significant role in the development of metabolic and cardiovascular drugs and cardiovascular safety issues in drug development. He was the ICH Expert Working Group PhRMA Topic Leader on the QT interval initiative (ICH E14), was the Chair of the Scientific Programs Committee of the FDA-sponsored Cardiac Safety Research Consortium (where he is also on the Executive Committee), and recently completed a 5-year term on the FDA Cardiovascular and Renal Drugs Advisory Committee, where he was also the Chair of the Committee.

Pharmaceutical positions have included VP, Clinical Research and Head of CV/Metabolic Clinical Development at Gilead Sciences, Chief Medical Officer of CardioDx, a molecular diagnostics company, Executive Director at AstraZeneca, and Director at the Schering-Plough Research Institute.